Latest Asx News

Emyria Limited announces key leadership shifts with Greg Hutchinson stepping up as Executive Chairman and Dr. Michael Winlo transitioning to Chief Scientific Officer, aiming to scale innovative mental health therapies amid growing demand.

Aeris Resources has completed a 70-hole drill program at its Constellation deposit, delivering impressive high-grade copper intercepts and setting the stage for a significant resource upgrade and mine permitting milestones.

Nanoveu has completed due diligence and is set to finalise its acquisition of EMASS, integrating cutting-edge AI-enabled SoC technology into its EyeFly3D™ platform to expand applications across wearables, IoT, and smart devices.

Pantoro Limited delivered a solid December quarter with gold production within guidance and positive cash flows for the fourth consecutive quarter, prompting an upward revision to its FY2025 production target. The company’s strategic focus on underground expansion and asset optimisation underpins its growth trajectory.

HyTerra Limited is set to launch the fully funded exploration phase of its Nemaha Project in Kansas, following a strategic investment from Fortescue Future Industries. The campaign will include leasing, geophysical surveys, and a multi-well drilling program, with operations scheduled to begin once winter conditions ease.

Mighty Kingdom Ltd has appointed Dylan Miklashek as Interim CEO and Duncan Gordon as Non-Executive Chair, signaling a fresh leadership approach amid a company restructuring.

Bell Financial Group has secured a significant agreement with Macquarie Bank to transfer approximately 75,000 online trading accounts, positioning Bell Direct and Desktop Broker for growth and earnings uplift in FY 2025.

Compumedics has locked in a pivotal five-year contract with Philips Australia, cementing Somfit as the leading device for pharmacy-based sleep testing and underpinning significant SaaS revenue growth through 2028.

Amcor plc has entered a definitive agreement to acquire Berry Global Group in a $9.9 billion all-stock transaction, aiming to create a global packaging leader. The merger, pending shareholder and regulatory approvals, is expected to close mid-2025.

Invex Therapeutics reports encouraging results from its collaboration with Tessara Therapeutics, showing Exenatide’s potential to improve neuronal survival in a 3D human brain model of Alzheimer's disease. The company maintains a stable cash position while exploring new neurological partnerships.

Bubs Australia has reported a strong Q2 FY25 performance with a positive EBITDA turnaround and robust revenue growth, while advancing its critical FDA clinical trial in the US.

LTR Pharma has inked a national distribution agreement with Symbion, positioning its innovative ED treatment SPONTAN® for broad pharmacy access across Australia ahead of its commercial launch.